Verucerfont

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameVerucerfont
Drug Alias Name瑞卢舍芳VerucerfontumCRF1-antagonist - GSK/NeurocrineGSK-561679AGSK-561679 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCorticotropin-releasing factor receptor 1 antagonists
TargetsCorticotropin-releasing factor receptor 1
Therapy Area/IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorDepressive Disorder +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcNational Institute On Alcohol Abuse And AlcoholismEmory University +[4] 
Active IndicationsN/A
Inactive IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorDepressive Disorder +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG